FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2190117163> ?p ?o ?g. }

• W2190117163 endingPage "43254" @default.
• W2190117163 startingPage "43244" @default.
• W2190117163 abstract "// Niamh Buckley 1,* , David Boyle 1,* , Darragh McArt 1 , Gareth Irwin 1 , D. Paul Harkin 1 , Tong Lioe 2 , Stephen McQuaid 1 , Jacqueline A. James 1 , Perry Maxwell 1 , Peter Hamilton 1 , Paul B. Mullan 1 and Manuel Salto-Tellez 1 1 Centre for Cancer Research and Cell Biology, Queen’s University Belfast, Belfast, United Kingdom 2 Department of Histopathology, Belfast City Hospital, Belfast, United Kingdom * These authors have contributed equally to this work Correspondence to: Manuel Salto-Tellez, email: // Keywords : pre-invasive breast cancer, DCIS, personalised medicine, biomarker, molecular pathology, Pathology Section Received : November 09, 2015 Accepted : November 27, 2015 Published : December 09, 2015 Abstract Breast cancer screening has led to a dramatic increase in the detection of pre-invasive breast lesions. While mastectomy is almost guaranteed to treat the disease, more conservative approaches could be as effective if patients can be stratified based on risk of co-existing or recurrent invasive disease. Here we use a range of biomarkers to interrogate and classify purely non-invasive lesions (PNL) and those with co-existing invasive breast cancer (CEIN). Apart from Ductal Carcinoma i n situ (DCIS), relative homogeneity is observed. DCIS contained a greater spread of molecular subtypes. Interestingly, high expression of p-mTOR was observed in all PNL with lower expression in DCIS and invasive carcinoma while the opposite expression pattern was observed for TOP2A. Comparing PNL with CEIN, we have identified p53 and Ki67 as predictors of CEIN with a combined PPV and NPV of 90.48% and 43.3% respectively. Furthermore, HER2 expression showed the best concordance between DCIS and its invasive counterpart. We propose that these biomarkers can be used to improve the management of patients with pre-invasive breast lesions following further validation and clinical trials. p53 and Ki67 could be used to stratify patients into low and high-risk groups for co-existing disease. Knowledge of expression of more actionable targets such as HER2 or TOP2A can be used to design chemoprevention or neo-adjuvant strategies. Increased knowledge of the molecular profile of pre-invasive lesions can only serve to enhance our understanding of the disease and, in the era of personalised medicine, bring us closer to improving breast cancer care." @default.
• W2190117163 created "2016-06-24" @default.
• W2190117163 creator A5014851181 @default.
• W2190117163 creator A5021836140 @default.
• W2190117163 creator A5028622747 @default.
• W2190117163 creator A5034722527 @default.
• W2190117163 creator A5039482198 @default.
• W2190117163 creator A5045420024 @default.
• W2190117163 creator A5048652049 @default.
• W2190117163 creator A5053522042 @default.
• W2190117163 creator A5055241025 @default.
• W2190117163 creator A5056362143 @default.
• W2190117163 creator A5063318340 @default.
• W2190117163 creator A5067880138 @default.
• W2190117163 date "2015-12-09" @default.
• W2190117163 modified "2023-10-15" @default.
• W2190117163 title "Molecular classification of non-invasive breast lesions for personalised therapy and chemoprevention" @default.
• W2190117163 cites W1444168786 @default.
• W2190117163 cites W1923770335 @default.
• W2190117163 cites W1949908926 @default.
• W2190117163 cites W1971820850 @default.
• W2190117163 cites W1974913655 @default.
• W2190117163 cites W1977305315 @default.
• W2190117163 cites W1982771674 @default.
• W2190117163 cites W1996200702 @default.
• W2190117163 cites W2004861918 @default.
• W2190117163 cites W2024489351 @default.
• W2190117163 cites W2029147710 @default.
• W2190117163 cites W2030796899 @default.
• W2190117163 cites W2050276844 @default.
• W2190117163 cites W2050627700 @default.
• W2190117163 cites W2053816046 @default.
• W2190117163 cites W2057246961 @default.
• W2190117163 cites W2068851566 @default.
• W2190117163 cites W2071036685 @default.
• W2190117163 cites W2095045586 @default.
• W2190117163 cites W2095783009 @default.
• W2190117163 cites W2097539177 @default.
• W2190117163 cites W2098827180 @default.
• W2190117163 cites W2103481912 @default.
• W2190117163 cites W2104297192 @default.
• W2190117163 cites W2117775530 @default.
• W2190117163 cites W2121692613 @default.
• W2190117163 cites W2126717458 @default.
• W2190117163 cites W2127445691 @default.
• W2190117163 cites W2127644335 @default.
• W2190117163 cites W2139672065 @default.
• W2190117163 cites W2140864342 @default.
• W2190117163 cites W2169491501 @default.
• W2190117163 cites W250128136 @default.
• W2190117163 doi "https://doi.org/10.18632/oncotarget.6525" @default.
• W2190117163 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4791229" @default.
• W2190117163 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26657114" @default.
• W2190117163 hasPublicationYear "2015" @default.
• W2190117163 type Work @default.
• W2190117163 sameAs 2190117163 @default.
• W2190117163 citedByCount "7" @default.
• W2190117163 countsByYear W21901171632017 @default.
• W2190117163 countsByYear W21901171632018 @default.
• W2190117163 countsByYear W21901171632019 @default.
• W2190117163 countsByYear W21901171632020 @default.
• W2190117163 countsByYear W21901171632023 @default.
• W2190117163 crossrefType "journal-article" @default.
• W2190117163 hasAuthorship W2190117163A5014851181 @default.
• W2190117163 hasAuthorship W2190117163A5021836140 @default.
• W2190117163 hasAuthorship W2190117163A5028622747 @default.
• W2190117163 hasAuthorship W2190117163A5034722527 @default.
• W2190117163 hasAuthorship W2190117163A5039482198 @default.
• W2190117163 hasAuthorship W2190117163A5045420024 @default.
• W2190117163 hasAuthorship W2190117163A5048652049 @default.
• W2190117163 hasAuthorship W2190117163A5053522042 @default.
• W2190117163 hasAuthorship W2190117163A5055241025 @default.
• W2190117163 hasAuthorship W2190117163A5056362143 @default.
• W2190117163 hasAuthorship W2190117163A5063318340 @default.
• W2190117163 hasAuthorship W2190117163A5067880138 @default.
• W2190117163 hasBestOaLocation W21901171631 @default.
• W2190117163 hasConcept C121608353 @default.
• W2190117163 hasConcept C126322002 @default.
• W2190117163 hasConcept C143998085 @default.
• W2190117163 hasConcept C2777757722 @default.
• W2190117163 hasConcept C2780862961 @default.
• W2190117163 hasConcept C2781197716 @default.
• W2190117163 hasConcept C29456083 @default.
• W2190117163 hasConcept C530470458 @default.
• W2190117163 hasConcept C55493867 @default.
• W2190117163 hasConcept C71924100 @default.
• W2190117163 hasConcept C86803240 @default.
• W2190117163 hasConceptScore W2190117163C121608353 @default.
• W2190117163 hasConceptScore W2190117163C126322002 @default.
• W2190117163 hasConceptScore W2190117163C143998085 @default.
• W2190117163 hasConceptScore W2190117163C2777757722 @default.
• W2190117163 hasConceptScore W2190117163C2780862961 @default.
• W2190117163 hasConceptScore W2190117163C2781197716 @default.
• W2190117163 hasConceptScore W2190117163C29456083 @default.
• W2190117163 hasConceptScore W2190117163C530470458 @default.
• W2190117163 hasConceptScore W2190117163C55493867 @default.
• W2190117163 hasConceptScore W2190117163C71924100 @default.
• W2190117163 hasConceptScore W2190117163C86803240 @default.

• next